call on doc compounded semaglutide CallonDoc Weight Loss: Safe & Effective Solution FDA Warns on Certain Forms
Description
In addition to treating obesity and Type 2 diabetes, GLP-1s have also shown promise with substance use disorders (SUD)
Frias JP, Nauck MA, Van J et al (2018) Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Week 24
That oversight is exactly what makes medically supervised programs safer and more effective than going it alone
